Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Meta Expands AI Training With Employee Activity Tracking Tools 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SEATTLE, March 01, 2016 -- Oncothyreon Inc. (Nasdaq:ONTY) announced today that Julie M. Eastland, President and Chief Financial Officer and Vice President, Corporate Development, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 8:00 a.m. Eastern Time in New York.
A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the “News & Events” section.
About Oncothyreon
Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our most advanced product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor. We are developing preclinical product candidates in oncology and immune-oncology using our protocell technology. For more information, visit www.oncothyreon.com.
CONTACT:
Investor Relations:
Julie Rathbun
Rathbun Communications
206-769-9219
[email protected]
Media Relations:
Kelly France, Ph.D.
BrewLife
415-946-1076
[email protected]
ONCOTHYREON INC., 2601 Fourth Avenue, Suite 500, Seattle, WA 98121
Tel: (206) 801-2100 Fax: (206) 801-2101
http://www.oncothyreon.com
